Lead Compound Masitinib

Tyrosine kinase inhibitors are the second generation of targeted therapies and represent a new and potent therapeutic option for numerous diseases.

The blockade of selected cell signaling pathways through protein kinase inhibitions can have therapeutic benefits in cancers, inflammatory diseases and central nervous system diseases.

The expertise developed by AB Science enables the selection of candidate drugs with two required characteristics:

•     being active against targeted tyrosine kinases known to be involved in specific diseases;

•     avoiding the inhibition of kinases necessary for normal cellular function, thereby limiting
      the risk of toxicity.

Masitinib has been developed by AB Science to match these requirements.

Masitinib is a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGFR, and Lyn.

Masitinib can address three potential therapeutic areas through several mechanisms of actions.

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.